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ABSTRACT
The Gleason score (GS) of prostate cancer on diagnostic biopsies is an important 
parameter for therapeutic decision-making. Biopsy GS under-estimates the actual GS at 
radical prostatectomy in a significant number of patients due to sampling artifact. The 
aim of this study was to identify markers that are differentially expressed in Gleason 
grade 3 (GG3) tumor glands embedded in GS 4 + 3 = 7 and GS 3 + 3 = 6 prostate 
cancer using laser capture microdissection and RNA sequencing.
GG3 tumor glands embedded in nine GS 3 + 3 = 6 and nine GS 4 + 3 = 7 prostate 
cancers were isolated by laser capture microdissection of frozen radical prostatectomy 
specimens. After RNA amplification and RNA sequencing, differentially expressed genes 
in both GG3 components were identified by a 2log fold change > 1.0 and p-value < 0.05. 
We applied  immunohistochemistry on a tissue micro-array representing 481 radical 
prostatectomy samples for further validation on protein level.
A total of 501 genes were up-regulated and 421 down-regulated in GG3 glands 
embedded in GS 4 + 3 = 7 as compared to GS 3 + 3 = 6 prostate cancer. We selected 
HELLS, ZIC2 and ZIC5 genes for further validation. ZIC5 mRNA was up-regulated 17 fold 
(p = 8.4E–07), ZIC2 8 fold (p = 1.3E–05) and HELLS 2 fold (p = 0.006) in GG3 glands 
derived from GS 4 + 3 = 7. HELLS expression of ≥ 1% occurred in 10% GS < 7, 17% GS 7 
and 43% GS >7 prostate cancer (p < 0.001). Using a cut-off of ≥ 1%, protein expression 
of ZIC5 was present in 28% GS < 7, 43% GS 7 and 57% GS > 7 cancer (p < 0.001).  
ZIC2 was neither associated with GS nor outcome in our validation set. HELLS was 
independently predictive for biochemical-recurrence after radical prostatectomy  
(HR 2.3; CI 1.5–3.6; p < 0.01).
In conclusion, HELLS and ZIC5 might be promising candidate markers for selection 
of biopsy GS 6 prostate cancer being at risk for up-grading at prostatectomy.
INTRODUCTION
With approximately 260,000 deaths per year 
worldwide, prostate cancer is a leading cause of 
cancer morbidity and mortality [1–3]. Prostate cancer 
demonstrates a highly variable disease course with many 
patients having asymptomatic disease. Pathologic grading 
of prostate cancer according to the Gleason grading 
system [4] is an important parameter for therapeutic 
decision-making [5]. The Gleason grading system 
has been used since the 1960s and is entirely based on 
tumor growth patterns. Increasing Gleason score (GS) is 
strongly associated with adverse histopathological and 
clinical endpoints, including pathologic stage, metastatic 
disease and survival [5]. Nevertheless, the prediction of 
tumor behavior and determination of optimal treatment 
modalities for GS 6 and 7 prostate cancer patients are 
uncertain [6–19]. 
While GS 6 prostate cancer demonstrates an indolent 
disease course in many patients, 55–90% of patients 
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still undergo radical prostatectomy [20]. A widely used 
alternative to surgery is active surveillance. Up to 33% of 
patients on active surveillance, however, will eventually 
undergo therapeutic intervention after a median follow-up 
of 1–4 years [10, 11, 21–23]. Therefore, more accurate 
stratification of GS 6 prostate cancer patients is needed. A 
caveat of current Gleason grading on diagnostic biopsies 
is sampling artifact. Up to 38% of the patients with GS 6 
prostate cancer on biopsy has GS ≥ 7 at subsequent radical 
prostatectomy [24, 25]. To optimize treatment decisions, 
it is essential to identify patients at risk for tumor under-
grading at diagnosis. 
GS 7 prostate cancer is composed of a mixture 
of regular tumor glands (Gleason grade 3) and aberrant 
glandular tumor structures (Gleason grade 4). Due to 
tumor heterogeneity, diagnostic biopsies might only 
sample Gleason grade 3 tumor areas leaving clinically 
relevant Gleason grade 4 patterns undiscovered. We 
hypothesize that Gleason grade 3 tumor glands embedded 
in GS 7 prostate cancer have different molecular 
expression profiles than Gleason grade 3 tumor glands 
embedded in GS 6 cancer. 
The aim of this study was to identify markers that 
are differentially expressed in Gleason grade 3 tumor 
glands embedded in GS 4 + 3 = 7 and GS 3 + 3 = 6 
prostate cancer using laser capture microdissection and 
RNA sequencing.
RESULTS
Gene-expression analysis
For each sample, RNA sequencing reads of 101 
nt were generated in paired-end fashion, which yielded 
27–130 million sequencing reads per sample (Table 1). 
Mapping rates between samples were comparable 
(58.6–73.2% of total reads mapped, of which 63.2–89.8% 
were mapped uniquely to the genome) and in total, 
between 2.4 and 19 million reads could be uniquely 
assigned to RefSeq genes. At a logCPM cut-off ≥ 1, 8133 
out of the total 23.373 annotated genes were detected. The 
workflow of the RNA sequence data was performed both 
on the CLC workbench, as well as TopHat and RefSeq, 
leading to approximately 80% of overlap in genes.
With regard to the limited number of samples, we 
determined the genes that were up-regulated in Gleason 
grade 3 derived from GS 4 + 3 = 7 prostate cancer as 
compared to Gleason grade 3 glands from GS 3 + 3 = 6 
tumors with a 2log fold change > 1.0 and p<0.05. A total 
of 501 genes were over-expressed in Gleason grade 3 
tumor glands being part of a GS 4 + 3 = 7 as compared to 
GS 3 + 3 = 6 prostate cancer and 421 genes were down-
regulated (Supplementary Tables 1 and 2). We selected 
the genes helicase, lymphoid specific (HELLS), and zinc 
finger of the cerebellum (ZIC) family members 2 and 5 for 
further validation. Selection of candidates was based on a) 
up-regulation in Gleason grade 3 in a GS 4 + 3 = 7 prostate 
cancer, b) commercial availability of a reliable antibody, c) 
novelty in clinical prostate cancer, d) staining reliability 
and heterogeneity on radical prostatectomy slides, and e) 
nuclear protein location. ZIC5 mRNA was up-regulated 17 
fold (p = 8.4E–07), ZIC2 8 fold (p = 1.3E–05) and HELLS 
2 fold (p = 0.006) in Gleason grade 3 tumor glands derived 
from GS 4 + 3 = 7 as compared to GS 3 + 3 = 6 prostate 
cancer. 
Immunohistochemical expression
Staining of HELLS was observed in the nuclei 
of lymphocytes (positive control) and was not 
expressed in placental tissues (negative control). No 
immunohistochemical staining of HELLS was observed 
in the nuclei of luminal or basal cells in benign prostate 
glands. Nuclear staining of HELLS was observed in 162 
out of 421 patients (39%), with the percentage of positive 
tumor nuclei varying between 0.2% and 9.3% (Figure 1A 
and 1B). A total of 64 out of 421 patients (15%) showed 
HELLS staining in ≥ 1% of tumor cells. HELLS 
expression of ≥ 1% was significantly associated with GS 
(p < 0.001; Table 1); 23 out of the 221 patients with GS 
< 7 (10%) expressed HELLS as compared to 29 out of the 
172 with GS 7 (17%) and 12 out of 28 patients with GS 
> 7 (43%). HELLS was expressed in > 1% of tumor cells 
in 8/30 (27%) GS 4 + 3 = 7 cases as compared to 20/142 
(14%) of GS 3 + 4 = 7 tumors (p = 0.09). In addition, 
HELLS was independently predictive for biochemical 
recurrence (HR 2.3; CI 1.5–3.6; p < 0.001) after radical 
prostatectomy adjusted for including age, PSA, GS, pT-
stage and surgical margin status in multivariate analysis 
(Table 2). HELLS was neither associated with PSA 
(p = 0.71) nor pT-stage (p = 0.07). 
The ZIC2 staining pattern demonstrated both 
cytoplasmatic and nuclear staining in most cases. As 
positive control, tubular epithelium in human kidney was 
used, and placenta tissue was used as negative control. 
In normal prostate glands, ZIC2 staining was observed 
in basal cells, as well as in luminal cells. In our cohort, 
315 cases could be scored for ZIC2 staining; cytoplasmic 
staining was seen with weak intensity in 197 (63%) and 
moderate intensity in 19 (6%) patients. Nuclear staining 
intensity varied from negative in 130 (41%), weak staining 
in 109 (35%), moderate staining in 69 (22%) and strong 
staining in 7 (2%) patients (Figure 1C and 1D). ZIC2 
protein expression (Table 2) was not associated with PSA 
(p = 0.66), GS (p = 0.18) or pT-stage (p = 0.77). ZIC2 did 
not have predictive value for biochemical recurrence after 
radical prostatectomy.
For ZIC5, basal cells in normal prostate glands 
were used as positive control tissue, whereas placental 
tissue served as negative control. Overall ZIC5 staining 
intensity was low. Of the 414 evaluable cases, 147 (36%) 
demonstrated nuclear staining of ZIC5. In 119 (29%) 
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Figure 1: Immunohistochemical expression of HELLS (A, B), ZIC2 (C, D) and ZIC5 (E, F) in prostate cancer. HELLS is 
positive in a small subpopulation of tumor cells (arrowheads). ZIC2 is negative (C) or moderately positive in a high percentage of cells with 
both cytoplasmatic and nuclear expression (D). ZIC5 shows sporadic (E) or moderate (F) nuclear expression in scattered cells. Original 
magnifications, 400×.
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Table 1: Mapping statistics
sample Gleason grade total Gleason score Total raw reads* mapped reads % mapped
EMC_1 3 3 + 3 = 6 91792508 35616115 0.388006775
EMC_3 3 3 + 3 = 6 80480262 33218341 0.412751402
EMC_5 3 3 + 3 = 6 61361596 24674668 0.402119071
EMC_11 3 4 + 3 = 7 44494648 15483302 0.347981222
EMC_13 3 3 + 3 = 6 27359166 9515977 0.347816779
EMC_14 3 4 + 3 = 7 46561926 18944840 0.406874063
EMC_15 3 4 + 3 = 7 39994636 14221623 0.355588259
EMC_16 3 3 + 3 = 6 75881474 28856468 0.38028344
EMC_17 3 3 + 3 = 6 59607656 24015364 0.402890595
EMC_18 3 4 + 3 = 7 39222968 13941906 0.355452601
EMC_19 3 4 + 3 = 7 92965194 40163311 0.432025248
EMC_21 3 4 + 3 = 7 82403308 35362238 0.429136146
EMC_23 3 3 + 3 = 6 90405938 38248796 0.42307836
EMC_24 3 3 + 3 = 6 108139494 47354477 0.437901781
EMC_25 3 4 + 3 = 7 87480724 37809613 0.432205076
EMC_27 3 4 + 3 = 7 80044030 33613406 0.419936452
EMC_28 3 3 + 3 = 6 89640362 37496355 0.418297675
EMC_29 3 4 + 3 = 7 92211070 40098913 0.434860077
*both strands included.
Table 1: continued
sample of which UMR of which MMR % UMR % MMR Assigned to RefSeq genes
EMC_1 14127736 21488379 0.396666958 0.603333042 10410480
EMC_3 12283062 20935279 0.369767473 0.630232527 9584359
EMC_5 9840075 14834593 0.3987926 0.6012074 4247549
EMC_11 7232723 8250579 0.467130526 0.532869474 2399724
EMC_13 4050156 5465821 0.425616413 0.574383587 3659443
EMC_14 7724933 11219907 0.40775921 0.59224079 4274365
EMC_15 5193919 9027704 0.365212817 0.634787183 3869535
EMC_16 11777779 17078689 0.408150401 0.591849599 4928250
EMC_17 9533194 14482170 0.396962295 0.603037705 6221822
EMC_18 4964691 8977215 0.356098442 0.643901558 5967889
EMC_19 12237918 27925393 0.304703912 0.695296088 17445060
EMC_21 11498196 23864042 0.325154647 0.674845353 12957564
EMC_23 12212986 26035810 0.319303802 0.680696198 15348892
EMC_24 14733626 32620851 0.311134806 0.688865194 15492077
EMC_25 11978513 25831100 0.316811309 0.683188691 13804904
EMC_27 12591218 21022188 0.374589174 0.625410826 5594209
EMC_28 13153841 24342514 0.350803191 0.649196809 12254753
EMC_29 12709260 27389653 0.316947744 0.683052256 13348694
UMR = uniquely mapping reads. MMR = multi-mapping reads.
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Table 2: Correlation of HELLS, ZIC2 and ZIC5 with clinicopathologic parameters
HELLS
Negative Positive Total p-value
PSA at diagnosis
 ≤ 10 ng/ml
 > 10 ng/ml
 Total
312 (74.3%)
44 (10.5%)
356 (84.8%)
55 (13.1%)
9 (2.1%)
64 (15.2%)
367 (87.4%)
53 (12.6%)
420
0.71
Gleason score
 < 7
 7
 > 7
 Total
198 (47.0%)
143 (34.0%)
16 (3.8%)
357 (84.8%)
23 (5.5%)
29 (6.8%)
12 (2.9%)
64 (15.2%)
221 (52.5%)
172 (40.8%)
28 (6.7%)
421
< 0.001
pT-stage
 pT2
 pT3a/b
 pT4
 Total
257 (61.1%)
81 (19.2%)
19 (4.5%)
357 (84.8%)
37 (8.8%)
21 (5.0%)
6 (1.4%)
64 (15.2%)
294 (69.9%)
102 (24.2%)
25 (5.9%)
421
0.07
ZIC2
Negative Positive Total p-value
PSA at diagnosis
 ≤ 10 ng/ml
 > 10 ng/ml
 Total
176 (52.9%)
32 (9.6%)
208 (62.5%)
108 (32.4%)
17 (5.1%)
125 (37.5%)
284 (85.3%)
49 (14.7%)
333
0.66
Gleason score
 < 7
 7
 > 7
 Total
98 (29.5%)
88 (26.4%)
22 (6.6%)
208 (62.5%)
61 (18.3%)
58 (17.4%)
6 (1.8%)
125 (37.5%)
159 (47.8%)
146 (43.8%)
28 (8.4%)
333
0.18
pT-stage
 pT2
 pT3a/b
 pT4
 Total
136 (40.9%)
58 (17.4%)
14 (4.2%)
208 (62.5%)
83 (24.9%)
36 (10.8%)
6 (1.8%)
125 (37.5%)
219 (65.8%)
94 (28.2%)
20 (6.0%)
333
0.77
ZIC5
Negative Positive Total p-value
PSA at diagnosis
 ≤ 10 ng/ml
 > 10 ng/ml
 Total
237 (57.4%)
30 (7.3%)
267 (64.7%)
122 (29.5%)
24 (5.8%)
146 (35.3%)
359 (86.9%)
54 (13.1%)
413
0.13
Gleason score
 < 7
 7
 > 7
 Total
161 (38.9%)
94 (22.7%)
12 (2.9%)
267 (64.5%)
61 (14.7%)
70 (16.9%)
16 (3.9%)
147 (35.5%)
222 (53.6%)
164 (39.6%)
28 (6.8%)
414
< 0.001
pT-stage
 pT2
 pT3a/b
 pT4
 Total
193 (46.6%)
58 (14.0%)
16 (3.9%)
267 (64.5%)
95 (23.0%)
42 (10.1%)
10 (2.4%)
147 (35.5)
288 (69.6%)
100 (24.1%)
26 (6.3%)
414
0.25
For HELLS and ZIC5 a cut-off of 1% was applied, for ZIC2 a cut-off of 50%.
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patients staining was weak, in 26 (6%) patients staining 
was moderate and in 2 (0.4%) strong. One-hundred 
patients (24%) showed nuclear ZIC5 staining in < 1% of 
the tumor cells, 32 patients (8%) expressed ZIC5 in 1–5% 
of the tumor cells and 15 patients (4%) expressed ZIC5 in 
> 5% of the tumor cells (Figure 1E and 1F). Using a cut-
off of ≥ 1%, protein expression of ZIC5 was associated 
with GS (p < 0.001; Table 1); 61 out of 222 patients 
with GS < 7 (28%) showed ZIC5 protein expression as 
compared to 58 out of 146 with GS 7 (43%), and 16 out 
of 28 with GS > 7 (57%). ZIC5 was expressed in > 1% 
of tumor cells in 15/29 (52%) of evaluable GS 4 + 3 = 7 
patients and 55/135 (41%) of GS 3 + 4 = 7 patients 
(p = 0.28). There was no significant association of ZIC5 
expression and PSA (p = 0.13) or pT-stage (p = 0.25). 
ZIC5 expression did not have predictive value for 
biochemical recurrence after operation (Table 3). 
Since HELLS is known to be involved in regulation 
of DNA methylation as well as histone modification, we 
analysed the relation of HELLS with Polycomb histone 
methyltransferase protein EZH2 [26]. Previously, we 
had shown that EZH2 expression in ≥ 1% of tumor cells 
was associated with high GS and biochemical recurrence 
[27, 28]. As we had determined EZH2 protein expression 
on the similar cohort, we analysed the expression of 
HELLS and EZH2 in similar tumor areas [27]. Using a 
cut-off of 1% for both HELLS and EZH2, we found a 
strong association between both proteins in the same 
patients (p = 0.004) and individual tissue-microarray 
punch cores (p = 0.03).
DISCUSSION
A major challenge in prostate cancer management is 
the decision on the optimal therapeutic approach in GS 6 
and 7  patients. The ERSPC has shown that prostate cancer 
screening can result in 20% risk reduction in disease-
specific mortality, however, at the cost of significant 
overtreatment [29]. On the other hand, 40% of GS 6 
prostate cancer patients under surveillance are switched to 
deferred treatment after a median of 7.5 years [30]. These 
results clearly demonstrate that better risk stratification is 
needed for GS 6 and 7 prostate cancer patients.
Current therapeutic stratification of prostate cancer 
patients predominantly relies on serum PSA level, biopsy 
GS and number of positive biopsies. Systematic biopsies 
might however, not be representative for the entire tumor 
and can lead to discordance of GS at diagnostic biopsy and 
radical prostatectomy. Fine and Epstein demonstrated that 
20% patients with GS 6 at biopsy were up-graded to GS 7 
(18.7%) or 8–10 (1.3%) at radical prostatectomy [31]. 
Helpap and Egevad found concordance between GS 6 
prostate cancer at biopsies and radical prostatectomies in 
only 28% [32]. The odds for up-grading are influenced by 
prostate volume, total number of biopsies taken, number 
of positive biopsies and biopsy tumor extent [33–35]. The 
objective of the current study was to identify differentially 
expressed genes in glandular Gleason grade 3 being part of 
GS 3 + 3 = 6 and GS 4 + 3 = 7 prostate cancer. 
For this purpose, we isolated Gleason grade 3 tumor 
glands from a total of 18 patients using LCM and analyzed 
gene-expression values after RNA sequencing. Since the 
numbers of samples in both groups were small (total 
N = 18), we determined the genes with a 2log-fold chance 
> 1 and p < 0.05, resulting in 501 genes over-expressed and 
421 genes down-regulated in Gleason grade 3 component 
of GS 3 + 3 = 6 as compared to GS 4 + 3 = 7 prostate 
cancer. The differentially expressed gene-list contained 
various genes previously reported to be differentially 
expressed in low- and intermediate/ high-grade prostate 
cancer such as HOXC6, MAGEC2, HERPUD1 and 
SATB1 [36–39]. From the differentially expressed genes, 
we selected ZIC2, ZIC5 and HELLS for further validation 
on protein level in an independent cohort of 481 radical 
prostatectomy samples. Interestingly, expression of ZIC2, 
ZIC5 and HELLS protein was generally low indicating 
a discordance between mRNA and protein levels. Of 
these three genes, HELLS and ZIC5 protein expression 
was strongly associated with GS ≥ 7 prostate cancer, 
while we were not able to confirm this relation on protein 
level for ZIC2. In addition, HELLS was an independent 
predictive marker for biochemical recurrence after radical 
prostatectomy. 
The zinc finger of the cerebellum (ZIC) family of 
genes encompasses five human homologues ZIC1–5 [40]. 
The family members are all transcription factors which 
have predominantly been implicated in neuro-ectodermal 
development [41]. ZIC family members are able to inhibit 
TCF4/β-Catenin and interact with GLI signaling [42, 
43]. In addition, ZIC family members are involved in 
various human solid tumors. ZIC1, −2 and −5 are over-
expressed in meningiomas, while ZIC4 is over-expressed 
in medulloblastomas [44]. High expression of ZIC2 is 
associated with survival in oral squamous carcinoma [45]. 
Methylation of ZIC4 in pTa bladder cancer is predictive 
for progression to muscle-invasive (≥ pT2) disease [46]. 
Promotor methylation of ZIC1 is associated with gastric 
cancer [47]. Interestingly, we found that ZIC1, ZIC2, 
ZIC4 and ZIC5 were all up-regulated in Gleason grade 3 
embedded in GS 4 + 3 = 7 prostate cancer on RNA level. 
While high ZIC5 was associated with GS ≥ 7 on protein 
level, we were not able to demonstrate this for ZIC2. 
The helicase, lymphoid specific (HELLS) gene also 
known as lymphoid-specific helicase (LSH) is known to 
activate E2F-transcription factors in G1/S-transition, and 
recruit DNA repair and chromatin-remodeling proteins 
[48]. HELLS has been implicated in the progression 
in non-small cell lung carcinoma and squamous cell 
carcinoma in the head and neck region [49–51]. Von Eyss 
et al. found that HELLS over-expression was associated 
with GS ≥ 4 + 3 = 7 tumors in 47 prostate cancer biopsies, 
which is in line with our study [52]. During development, 
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HELLS is involved in silencing of HOX genes by 
recruitment of DNA methyltransferases and Polycomb-
repressive complex members among which EZH2 [26]. 
Interestingly, EZH2 demonstrates similar expression 
patterns in prostate cancer as HELLS with expression in a 
minority of tumor cells. Using a cut-off of ≥ 1% in radical 
prostatectomy specimens, we found that EZH2 expression 
was associated with high-grade prostate cancer and 
biochemical recurrence [27, 28]. EZH2 expression in < 1% 
of tumor cells in prostate cancer biopsies was predictive 
for indolent disease at radical prostatectomy [19]. 
Although we did not perform immunofluorescent 
co-expression studies, we found statistical correlation of 
HELLS and EZH2 expression within the same patients 
and individual tissue microarray cores, suggesting a link 
of both DNA- and histone- methylation pathways within 
prostate cancer patients as has previously been shown in 
in vitro models [26].
In this study, we have analyzed gene-expression 
profiles in Gleason grade 3 in GS 3 + 3 = 6 and GS 
4 + 3 = 7 prostate cancer using LCM, RNA amplification 
and sequencing. Hereby, we demonstrate the feasibility of 
this methodology for in-depth analysis of specific cellular 
tissue compartments. Our validation of a selected panel of 
genes by QPCR and the differential expression of various 
known genes such as HOXC6 and HERPUD1 supports 
the validity of this methodology. Using this approach, we 
were able to identify genes of interest that might have been 
undetected due to background signal when conventional 
whole tissue slide profiling is applied.
A caveat of the current study was the relatively 
low number of samples in both cohorts, which hampered 
robust biostatistical analysis. Therefore, we set less 
stringent discriminatory criteria for comparing both study 
groups and selected a panel of genes for further validation. 
We applied immunohistochemistry for validation of 
differential gene-expression profiles and did not include a 
validation by QPCR on independent laser microdissected 
patients samples. While our purpose was to validate genes 
such as HELLS and ZIC5 immunohistochemically on 
diagnostic GS 3 + 3 = 6 biopsies to select patients with 
actual GS ≥ 7 disease, biopsy validation was not included 
in the current study. Since retrospective biopsy studies are 
hampered by the fact that a significant number of biopsies 
will not have representative tissue available anymore, we 
are currently analyzing the predictive value of HELLS and 
ZIC5 in a prospective biopsy study.
In conclusion, we demonstrated that combining 
LCM, RNA amplification and sequencing resulted 
in reliable molecular profiling of specific tissue 
compartments. We found that in particular ZIC family 
members are over-expressed in Gleason grade 3 tumor 
glands associated with GS 4 + 3 = 7 disease. ZIC5 and 
HELLS were associated with GS ≥ 7 prostate cancer, 
while HELLS was independently predictive for post-
operative biochemical recurrence. 
MATERIAL AND METHODS
Clinical specimens
We selected 18 radical prostatectomy specimens 
of men who had been operated for prostate cancer at 
Erasmus Medical Center between 2005 and 2011. Directly 
after surgery, the prostate was transported on ice to the 
pathology department where a transverse tissue slide was 
snap frozen in liquid nitrogen for research purposes. The 
remaining prostate was injected with neutral-buffered 
formalin (4%) to allow for fast and equal fixation, and 
processed for routine pathologic diagnosis. For this study, 
Table 3: Predictive value of HELLS, ZIC2 and ZIC5 for biochemical recurrence after radical 
prostatectomy
Parameter
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age 1.0 (1.0–1.09) 0.04 1.0 (1.0–1.1) 0.21
PSA 3.5 (2.3–5.3) < 0.01 1.8 (1.1–2.8) 0.03
Gleason score 2.5 (1.9–3.3) < 0.01 1.8 (1.3–2.5) < 0.01
pT-stage 1.7 (1.5–2.0) < 0.01 1.3 (1.0–1.5) 0.03
Surgical margin 3.3 (2.3–4.7) < 0.01 2.3 (1.6–3.4) < 0.01
HELLS 2.6 (1.7–4.0) < 0.01 2.3 (1.5–3.6) < 0.01
ZIC2 1.1 (0.7–1.7) 0.69 1.4 (0.9–2.2) 0.11
ZIC5 1.3 (0.9–1.9) 0.15 0.9 (0.6–1.3) 0.61
HR = Hazard ratio; CI = Confidence Interval; PSA = Prostate Specific Antigen.
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we selected nine patients with GS 3 + 3 = 6 prostate 
cancer and nine patients with GS 4 + 3 = 7. Selection 
was based on availability of tissues and estimated tumor 
percentage in the frozen tissue. Reference hematoxylin/ 
eosin (HE) staining was performed on the frozen tissue 
samples to verify the Gleason grade and estimate the 
tumor’s percentage. 
For validation purposes, we used tissue microarrays 
containing samples of 481 radical prostatectomy specimens 
in triplicate, as described previously [27, 53, 54]. 
Clinical follow-up was recorded after each control visit 
at our outpatient clinic and data were transmitted to 
the central study database. Post-operative biochemical 
recurrence was defined as an increase in serum Prostate 
Specific Antigen (PSA) after two different measurements, 
at least three months apart. The use of tissue samples for 
scientific purposes was approved by institutional board 
review (MEC-2011-295, MEC-2011-296). Samples were 
used according to the “Code for Proper Secondary Use of 
Human Tissue in The Netherlands” as developed by the 
Dutch Federation of Medical Scientific Societies (FMWV, 
version 2002, update 2011).
Laser capture microdissection
For laser capture microdissection (LCM), we cut 
10 µm thick tissue sections from the frozen tumor slices. 
After every two 10 µm thick slide, a 5 µm thick slide 
was made for HE reference evaluation. Each section was 
mounted on a glass slide (MembraneSlide, 1.0mm PEN-
membrane covered; Zeiss Micro-Imaging GmbH, Munich, 
Germany) and air-dried for 10 minutes. All glass slides 
had been treated with UV-light for 30 minutes. After 
drying, each glass slide was individually packed in tinfoil 
and stored at −80ºC until further use. All materials and 
the cryostate had been cleaned with 70% ethanol prior to 
tissue handling.
For LCM, each slide was individually taken out of 
−80°C storage, unwrapped and immersed in RNAlater 
Solution (Stabilization Solution; Ambion, UK). Slides 
were stained with Mayer’s Hematoxylin for 30 seconds 
and dehydrated in a 50%–100% ethanol/MilliQ H2O 
gradient. Slides were air-dried and dissected at the PALM 
laser capture microdissection microscope (PALM Axio 
Observer A1, Zeiss Micro-Imaging, Munich, Germany) for 
a maximum of 60 minutes at room temperature. Individual 
tumor glands with Gleason grade 3 were carefully selected 
and dissected, to prevent contamination with surrounding 
normal stromal tissue or other tumor grade components. 
Dissected elements were automatically catapulted into 
the lid of a 500 µl eppendorf (AdhesiveCap opaque; Zeiss 
Micro-Imaging, Munich, Germany). 65 µl RLT+ buffer 
(from Qiagen AllPrep DNA/RNA Micro Kit; Qiagen, 
Venlo, The Netherlands) was added and samples were 
stored at −80ºC until further use. 
RNA isolation
After dissection and storing, the 10 individually 
dissected samples from each patient were pooled resulting 
in 9 samples with Gleason grade 3 tumor glands derived 
from GS 3 + 3 = 6 prostate cancer, and 9 Gleason grade 
3 samples derived from GS 4 + 3 = 7 prostate cancer. 
The total amount of RLT+ buffer after pooling was 
complemented to 650 µl. For RNA isolation the Qiagen 
AllPrep micro kit was used (Qiagen AllPrep DNA/RNA 
Micro Kit; Qiagen, Venlo, The Netherlands) according to 
the manufacturer’s guidelines. RNA quality and quantity 
was measured using the Nanodrop Spectrophotometer 
(Model ND-1000, NanoDrop Technologies, Wilmington, 
USA) and Bioalalyzer Nanochip or Picochip (RNA 
6000 Nano/Pico Kit, Agilent Technologies, Waldbronn, 
Germany). The average RNA amount harvested for the 
GS 3 + 3 = 6 group was 80.5 ng (2.9–240.0 ng) with RNA 
Integrity Number (RIN) values between 1.0 and 7.0. For 
the Gleason grade 3 samples derived from GS 4 + 3 = 7 
prostate cancer, the average RNA amount was 35.4 ng 
(10.3–76.7 ng) with RIN values between 1.0 and 5.2. 
RNA sequencing
RNA amplification and sequencing was performed 
by AROS (AROS Applied Biotechnology A/S, Aarhus, 
Denmark). Amplification was performed using NuGEN’s 
Ovation RNA-seq v2 System to generate double stranded 
cDNA. A control sample (10 ng of human reference RNA) 
was included. All samples produced similar amounts of 
double stranded cDNA (measured with the Qubit BR 
dsDNA kit). 1.2 µg of the dsDNA was used as input for 
the DNA TruSeq library prep to produce the library.
Data workflow 
All RNA sequence data were aligned to pre-indexed 
human reference genome (hg19, available via the bowtie2 
homepage including annotation) using TopHat version 
2.0.4 [55]. To increase accuracy, reads were aligned 
against the indexed transcriptome prior to alignment to 
the genome via setting “—transcriptome-index”. Other 
specified TopHat2 settings were “—b2-very-sensitive 
—report-secondary-alignments —read-realign-edit-dist 
1—mate-inner-dist 200 —mate-std-dev 50”. RNA 
expression levels were quantified via HTSeq-count (http://
www-huber.embl.de/users/anders/HTSeq, version 0.5.4p1) 
using the UCSC hg19 annotation provided by the TopHat2 
developers. Subsequently, we used edgeR (version 3.0.4) 
to investigate differentially expressed genes between 
our different Gleason grade groups [56]. For internal 
validation purposes, we additionally performed RNA-
sequence analysis using CLC Genomics Workbench 
version 5.1 (Qiagen, Venlo, The Netherlands). We 
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followed the outlined RNA-sequence analysis pipeline and 
used hg19 as reference genome. All TopHat2 alignments 
were performed on the High Performance Cloud (https://
www.surfsara.nl/systems/hpc-cloud). Downstream 
analyses as well as the CLC Genomics Workbench were 
run on a Dell Precision with two Intel Xeon, 8 Hexacores 
and 128 GB RAM shared by Windows 7 64-bit and a 
Linux Mint 12 64-bit virtual machine (VirtualBox v. 
4.2.6). To verify whether expression value differences 
after RNA amplification and sequencing were in line with 
original expression values, we performed quantitative PCR 
for ZIC2 (HS00600854_m1), ZIC5 (HS00741567_m1) 
and MYT1 (HS01027966_m1) in the stock solutions, 
which all showed comparable RNA read counts.
Immunohistochemistry
Tissue slides (5 μm) were mounted on 
aminoacetylsilane coated glass slides (Starfrost; Berlin, 
Germany), deparaffinised in xylene and rehydrated in 
ethanol. Endogenous peroxidase activity was blocked 
by 1% hydrogen peroxide in methanol for 20 minutes. 
Microwave (700 W) pretreatment in tris(hydroxymethyl)-
aminomethane-EDTA (pH 9.0) was performed for 
15 minutes. Slides were incubated with primary 
antibody targeting HELLS (1:500, clone H4, sc46665, 
Santa Cruz, Germany), ZIC2 (1:1000, ab15392, Merck 
Millipore, Amsterdam, The Netherlands) and ZIC5 
(1:100; ab115566, Abcam, Cambridge, UK) followed by 
chromogenic visualization using the EnVision DAKO kit 
(DAKO, Glostrup, Denmark). Antibody specificity was 
tested using Western blotting and immunohistochemistry 
of positive and negative control tissues indicated by the 
manufacturer›s product sheets as well as the Human 
Protein Atlas www.proteinatlas.org. After counterstaining 
with hematoxylin, slides were thoroughly washed, 
dehydrated, cleared in xylene and mounted in malinol 
(Chroma-Geselschaft, Körgen, Germany). Antibody 
expression was scored by one investigator (MH) in a 
blinded setting. Cellular location, percentage of positive 
tumor cells and staining intensity were determined for all 
antibodies. Staining intensity was scored as negative (0; 
no staining), weak (1+; only visible at high magnification), 
moderate (2+; visible at low magnification) and strong 
(3+; striking at low magnification).
Statistics
For each immunohistochemical parameter, the average 
of the tissue microarray scores was calculated per patient. 
Statistical associations between marker expression and 
continuous clinicopathologic parameters (age and PSA at 
time of diagnosis) were analyzed using Student’s t-test, and 
with categorical parameters (Gleason score, pT-stage and 
surgical margins) using Pearson’s Chi-square (Χ2) test. To 
determine whether expression was predictive for biochemical 
recurrence, we used uni- and multivariate Cox regression 
with stepwise backward entering of covariates. A two-sided 
p-value < 0.05 was considered significant. All statistics were 
performed using SPSS 20 (SPSS; Chicago, USA).
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